Top Story

IGHV mutation without 11q, 17p deletions defines very low-risk CLL subgroup

December 1, 2015

Read the Perspective from Kanti R. Rai, MD

Patients with chronic lymphocytic leukemia who harbor IGHV mutations and lack 11q or 17p chromosome deletions may experience a durable remission following first-line treatment with fludarabine, cyclophosphamide and rituximab, according to results of a retrospective observational analysis.

Researchers have sought to identify a subgroup of patients most likely to benefit from fludarabine, cyclophosphamide and rituximab (Rituxan; Genentech, Biogen Idec), or FCR, the standard regimen for untreated patients with CLL who are young and in good physical condition.

NCCN appoints interim VP of oncology research program

December 1, 2015
The National Comprehensive Cancer Network appointed Robert C. Young, MD, as interim vice president of the NCCN Oncology Research Program. Young — recognized for…

Early, open communication required when involving adolescents in cancer care plans

December 1, 2015
When an adolescent or young adult receives a cancer diagnosis, their life is completely interrupted.They miss school for periods of time, they may lose their hair, and…
Meeting News Coverage

Top Takeaways from ASCO: Esophageal cancer

December 1, 2015
CHICAGO — Heart disease-related death among patients with esophageal cancer who are treated with radiation may be detectable as early as 8 months from diagnosis…
FDA News

FDA grants orphan drug designation to marizomib for malignant glioma

December 1, 2015
The FDA granted orphan drug designation to marizomib for the treatment of patients with malignant glioma, according to a press release from the drug’s…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Meeting News Coverage Video

HPV vaccination falling short due to providers, not parents

November 22, 2015
More »

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan